Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

14.3%

6 terminated/withdrawn out of 42 trials

Success Rate

85.4%

-1.1% vs industry average

Late-Stage Pipeline

43%

18 trials in Phase 3/4

Results Transparency

83%

29 of 35 completed trials have results

Key Signals

1 recruiting29 with results6 terminated

Enrollment Performance

Analytics

Phase 2

18(42.9%)

Phase 3

15(35.7%)

Phase 4

3(7.1%)

N/A

3(7.1%)

Phase 1

3(7.1%)

42Total

Phase 2(18)

Phase 3(15)

Phase 4(3)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (42)

Showing 20 of 42 trials

NCT05796388Not ApplicableRecruiting

A Study of Virtual Reality and Linaclotide for IBS-C

Role: collaborator

NCT05760313Phase 2Completed

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Role: collaborator

NCT04166058Phase 3Completed

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Role: collaborator

NCT05652205Phase 3Completed

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Role: collaborator

NCT05740007Phase 2Terminated

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Role: lead

NCT04026113Phase 3Completed

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Role: collaborator

NCT05362695Phase 1Completed

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

Role: lead

NCT05188261Phase 1Completed

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

Role: lead

NCT01107236Phase 2Completed

Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction

Role: lead

NCT04110145Phase 2Completed

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Role: collaborator

NCT02837783Phase 4Terminated

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

Role: lead

NCT03226899Phase 4Terminated

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Role: lead

NCT03561090Phase 3Terminated

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Role: lead

NCT03561883Phase 3Completed

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Role: lead

NCT03931785Phase 2Completed

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Role: lead

NCT02559817Phase 2Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Role: collaborator

NCT03573908Phase 3Completed

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Role: lead

NCT02559206Phase 2Completed

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Role: lead

NCT02637557Phase 2Completed

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Role: lead

NCT02590432Phase 4Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Role: collaborator